63 participants
Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-04
- Start Date:
- 2018-08-30
- Completion:
- 2026-12-30
Conditions
- Glioblastoma
Interventions
- DRUG
No Results Yet